Skip to main content
Top
Published in: Digestive Diseases and Sciences 10/2022

10-01-2022 | Statins | Original Article

Simvastatin Inhibits Histologic Changes Associated with Gastroduodenal Reflux in a Murine Model

Authors: Anna K. Gergen, Helen J. Madsen, Anqi Li, Linling Cheng, Xianzhong Meng, David A. Fullerton, Akshay Pratap, Michael J. Weyant

Published in: Digestive Diseases and Sciences | Issue 10/2022

Login to get access

Abstract

Background

Observational studies demonstrate a protective effect of statins on the development and progression of esophageal adenocarcinoma. The role of statins in the prevention of reflux-induced esophageal changes remains unknown.

Aims

Using a mixed gastroduodenal reflux mouse model, we hypothesized that oral administration of simvastatin would attenuate reflux-induced mucosal changes of the distal esophagus.

Methods

Human Barrett’s (CPB) and esophageal adenocarcinoma (FLO1 and OE19) cells were treated with simvastatin. Cell proliferation and apoptosis were evaluated using the MTS proliferation and annexin V apoptosis assays, respectively. A reflux mouse model was generated by performing a side-to-side anastomosis between the gastroesophageal junction and first portion of the duodenum (duodeno-gastroesophageal anastomosis, DGEA). DGEA mice were fed a standard or simvastatin-containing diet following surgery. Mice were euthanized 6 weeks post-operatively.

Results

Simvastatin significantly decreased proliferation and increased apoptosis in all cell lines. Compared to control animals, mice undergoing DGEA who were fed a standard diet demonstrated a fourfold increase in mucosal thickness and significant increase in proliferating cells (p < 0.0001). DGEA mice fed a simvastatin-containing diet had an attenuated response to reflux, with a significant reduction in mucosal hyperplasia and proliferation (p < 0.0001). DGEA mice fed a simvastatin-containing diet demonstrated significant upregulation of procaspase-3 (p = 0.009) and cleaved caspase-3 (p = 0.034) in the distal esophagus.

Conclusions

We demonstrate for the first time a reduction in reflux-induced histologic changes of the distal esophagus following oral administration of simvastatin in vivo. These findings identify simvastatin as a potential preventative agent to inhibit the development and progression of reflux-induced esophageal injury.
Literature
1.
go back to reference Ogunwobi OO, Beales IL. Statins inhibit proliferation and induce apoptosis in Barrett’s esophageal adenocarcinoma cells. Am J Gastroenterol 2008;103:825–837.CrossRef Ogunwobi OO, Beales IL. Statins inhibit proliferation and induce apoptosis in Barrett’s esophageal adenocarcinoma cells. Am J Gastroenterol 2008;103:825–837.CrossRef
2.
go back to reference Antonopoulos AS, Margaritis M, Lee R, Channon K, Antoniades C. Statins as anti-inflammatory agents in atherogenesis: molecular mechanisms and lessons from the recent clinical trials. Curr Pharm Des 2012;18:1519–1530.CrossRef Antonopoulos AS, Margaritis M, Lee R, Channon K, Antoniades C. Statins as anti-inflammatory agents in atherogenesis: molecular mechanisms and lessons from the recent clinical trials. Curr Pharm Des 2012;18:1519–1530.CrossRef
3.
go back to reference Diamantis E, Kyriakos G, Quiles-Sanchez LV, Farmaki P, Troupis T. The anti-inflammatory effects of statins on coronary artery disease: an updated review of the literature. Curr Cardiol Rev 2017;13:209–216.CrossRef Diamantis E, Kyriakos G, Quiles-Sanchez LV, Farmaki P, Troupis T. The anti-inflammatory effects of statins on coronary artery disease: an updated review of the literature. Curr Cardiol Rev 2017;13:209–216.CrossRef
4.
go back to reference Graaf MR, Richel DJ, van Noorden CJF, Guchelaar H-J. Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer. Cancer Treat Rev 2004;30:609–641.CrossRef Graaf MR, Richel DJ, van Noorden CJF, Guchelaar H-J. Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer. Cancer Treat Rev 2004;30:609–641.CrossRef
5.
go back to reference Boudreau DM, Yu O, Johnson J. Statin use and cancer risk: a comprehensive review. Expert Opin Drug Saf 2010;9:603–621.CrossRef Boudreau DM, Yu O, Johnson J. Statin use and cancer risk: a comprehensive review. Expert Opin Drug Saf 2010;9:603–621.CrossRef
6.
go back to reference Fatehi HA. Current perspectives on statins as potential anti-cancer therapeutics: clinical outcomes and underlying molecular mechanisms. Transl Lung Cancer Res 2019;8:692–699.CrossRef Fatehi HA. Current perspectives on statins as potential anti-cancer therapeutics: clinical outcomes and underlying molecular mechanisms. Transl Lung Cancer Res 2019;8:692–699.CrossRef
7.
go back to reference Konturek PC, Burnat G, Hahn EG. Inhibition of Barret’s adenocarcinoma cell growth by simvastatin: involvement of COX-2 and apoptosis-related proteins. J Physiol Pharmacol 2007;58:141–148.PubMed Konturek PC, Burnat G, Hahn EG. Inhibition of Barret’s adenocarcinoma cell growth by simvastatin: involvement of COX-2 and apoptosis-related proteins. J Physiol Pharmacol 2007;58:141–148.PubMed
8.
go back to reference Sadaria MR, Reppert AE, Yu JA, Meng X, Fullerton DA, Reece TB et al. Statin therapy attenuates growth and malignant potential of human esophageal adenocarcinoma cells. J Thorac Cardiovasc Surg 2011;142:1152–1160.CrossRef Sadaria MR, Reppert AE, Yu JA, Meng X, Fullerton DA, Reece TB et al. Statin therapy attenuates growth and malignant potential of human esophageal adenocarcinoma cells. J Thorac Cardiovasc Surg 2011;142:1152–1160.CrossRef
9.
go back to reference Chen Y, Li L-B, Zhang J, Tang D-P, Wei J-J, Zhuang Z-H. Simvastatin, but not pravastatin, inhibits the proliferation of esophageal adenocarcinoma and squamous cell carcinoma cells: a cell-molecular study. Lipids Health Dis 2018;17:290.CrossRef Chen Y, Li L-B, Zhang J, Tang D-P, Wei J-J, Zhuang Z-H. Simvastatin, but not pravastatin, inhibits the proliferation of esophageal adenocarcinoma and squamous cell carcinoma cells: a cell-molecular study. Lipids Health Dis 2018;17:290.CrossRef
10.
go back to reference Yu JA, Li H, Meng X, Fullerton DA, Nemenoff RA, Mitchell JD et al. Group IIa secretory phospholipase expression correlates with group IIa secretory phospholipase inhibition-mediated cell death in K-ras mutant lung cancer cells. J Thorac Cardiovasc Surg 2012;144:1479–1485.CrossRef Yu JA, Li H, Meng X, Fullerton DA, Nemenoff RA, Mitchell JD et al. Group IIa secretory phospholipase expression correlates with group IIa secretory phospholipase inhibition-mediated cell death in K-ras mutant lung cancer cells. J Thorac Cardiovasc Surg 2012;144:1479–1485.CrossRef
11.
go back to reference Babu A, Meng X, Banerjee AM, Gamboni-Robertson F, Cleveland JC, Damle S et al. Secretory phospholipase A2 is required to produce histologic changes associated with gastroduodenal reflux in a murine model. J Thorac Cardiovasc Surg 2008;135:1220–1227.CrossRef Babu A, Meng X, Banerjee AM, Gamboni-Robertson F, Cleveland JC, Damle S et al. Secretory phospholipase A2 is required to produce histologic changes associated with gastroduodenal reflux in a murine model. J Thorac Cardiovasc Surg 2008;135:1220–1227.CrossRef
12.
go back to reference McKay A, Leung BP, McInnes IB, Thomson NC, Liew FY. A novel anti-inflammatory role of simvastatin in a murine model of allergic asthma. J Immunol 2004;172:2903–2908.CrossRef McKay A, Leung BP, McInnes IB, Thomson NC, Liew FY. A novel anti-inflammatory role of simvastatin in a murine model of allergic asthma. J Immunol 2004;172:2903–2908.CrossRef
13.
go back to reference Bruner-Tran KL, Osteen KG, Duleba AJ. Simvastatin protects against the development of endometriosis in a nude mouse model. J Clin Endocrinol Metab 2009;94:2489–2494.CrossRef Bruner-Tran KL, Osteen KG, Duleba AJ. Simvastatin protects against the development of endometriosis in a nude mouse model. J Clin Endocrinol Metab 2009;94:2489–2494.CrossRef
14.
go back to reference Zhang X, Mao S, Luo G, Wei J, Berggren-Söderlund M, Nilsson-Ehle P et al. Effects of simvastatin on apolipoprotein M in vivo and in vitro. Lipids Health Dis 2011;10:112.CrossRef Zhang X, Mao S, Luo G, Wei J, Berggren-Söderlund M, Nilsson-Ehle P et al. Effects of simvastatin on apolipoprotein M in vivo and in vitro. Lipids Health Dis 2011;10:112.CrossRef
15.
go back to reference Highlights of Prescribing Information. Zocor (simvastatin) Tablets. Merck Sharp & Dohme LTD. 2015. Highlights of Prescribing Information. Zocor (simvastatin) Tablets. Merck Sharp & Dohme LTD. 2015.
17.
go back to reference Thomas T, Loke Y, Beales ILP. Systematic review and meta-analysis: use of statins is associated with a reduced incidence of oesophageal adenocarcinoma. J Gastrointest Cancer 2018;49:442–454.CrossRef Thomas T, Loke Y, Beales ILP. Systematic review and meta-analysis: use of statins is associated with a reduced incidence of oesophageal adenocarcinoma. J Gastrointest Cancer 2018;49:442–454.CrossRef
18.
go back to reference Singh S, Singh AG, Singh PP, Murad MH, Iyer PG. Statins are associated with reduced risk of esophageal cancer, particularly in patients with Barrett’s esophagus: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2013;11:620–629.CrossRef Singh S, Singh AG, Singh PP, Murad MH, Iyer PG. Statins are associated with reduced risk of esophageal cancer, particularly in patients with Barrett’s esophagus: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2013;11:620–629.CrossRef
19.
go back to reference Deng H-Y, Lan X, Zheng X, Zha P, Zhou J, Wang R-L et al. The association between statin use and survival of esophageal cancer patients: a systematic review and meta-analysis. Medicine 2019;98:e16480.CrossRef Deng H-Y, Lan X, Zheng X, Zha P, Zhou J, Wang R-L et al. The association between statin use and survival of esophageal cancer patients: a systematic review and meta-analysis. Medicine 2019;98:e16480.CrossRef
20.
go back to reference Zhang HY, Spechler SJ, Souza RF. Esophageal adenocarcinoma arising in Barrett esophagus. Cancer Lett 2009;275:170–177.CrossRef Zhang HY, Spechler SJ, Souza RF. Esophageal adenocarcinoma arising in Barrett esophagus. Cancer Lett 2009;275:170–177.CrossRef
21.
go back to reference Goldstein SR, Yang GY, Curtis SK, Reuhl KR, Liu BC, Mirvish SS et al. Development of esophageal metaplasia and adenocarcinoma in a rat surgical model without the use of a carcinogen. Carcinogenesis 1997;18:2265–2270.CrossRef Goldstein SR, Yang GY, Curtis SK, Reuhl KR, Liu BC, Mirvish SS et al. Development of esophageal metaplasia and adenocarcinoma in a rat surgical model without the use of a carcinogen. Carcinogenesis 1997;18:2265–2270.CrossRef
22.
go back to reference Chen X, Yang G, Ding WY, Bondoc F, Curtis SK, Yang CS. An esophagogastroduodenal anastomosis model for esophageal adenocarcinogenesis in rats and enhancement by iron overload. Carcinogenesis 1999;20:1801–1808.CrossRef Chen X, Yang G, Ding WY, Bondoc F, Curtis SK, Yang CS. An esophagogastroduodenal anastomosis model for esophageal adenocarcinogenesis in rats and enhancement by iron overload. Carcinogenesis 1999;20:1801–1808.CrossRef
23.
go back to reference Garman KS, Orlando RC, Chen X. Review: experimental models for Barrett’s esophagus and esophageal adenocarcinoma. Am J Physiol Gastrointest Liver Physiol 2012;302:G1231–G1243.CrossRef Garman KS, Orlando RC, Chen X. Review: experimental models for Barrett’s esophagus and esophageal adenocarcinoma. Am J Physiol Gastrointest Liver Physiol 2012;302:G1231–G1243.CrossRef
24.
go back to reference He J, Fang Y, Chen X. Surgical models of gastroesophageal reflux with mice. J Vis Exp 2015;102:e53012–e53112. He J, Fang Y, Chen X. Surgical models of gastroesophageal reflux with mice. J Vis Exp 2015;102:e53012–e53112.
25.
go back to reference Mason RP. Molecular basis of differences among statins and a comparison with antioxidant vitamins. Am J Cardiol 2006;98:S34–S41.CrossRef Mason RP. Molecular basis of differences among statins and a comparison with antioxidant vitamins. Am J Cardiol 2006;98:S34–S41.CrossRef
Metadata
Title
Simvastatin Inhibits Histologic Changes Associated with Gastroduodenal Reflux in a Murine Model
Authors
Anna K. Gergen
Helen J. Madsen
Anqi Li
Linling Cheng
Xianzhong Meng
David A. Fullerton
Akshay Pratap
Michael J. Weyant
Publication date
10-01-2022
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 10/2022
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-021-07344-0

Other articles of this Issue 10/2022

Digestive Diseases and Sciences 10/2022 Go to the issue